These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20378673)

  • 1. Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation.
    Nix DE; Matthias KR
    J Antimicrob Chemother; 2010 Jun; 65(6):1311-2. PubMed ID: 20378673
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis.
    Cunha BA
    J Clin Microbiol; 2009 May; 47(5):1613. PubMed ID: 19403778
    [No Abstract]   [Full Text] [Related]  

  • 3. Tigecycline for the treatment of Acinetobacter infections: a case series.
    Gallagher JC; Rouse HM
    Ann Pharmacother; 2008 Sep; 42(9):1188-94. PubMed ID: 18614749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tigecycline treatment for urinary tract infections: case report and literature review.
    Drekonja DM; Johnson JR
    J Chemother; 2011 Jun; 23(3):168-70. PubMed ID: 21742587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model.
    Koomanachai P; Kim A; Nicolau DP
    J Antimicrob Chemother; 2009 May; 63(5):982-7. PubMed ID: 19279050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid development of Acinetobacter baumannii resistance to tigecycline.
    Reid GE; Grim SA; Aldeza CA; Janda WM; Clark NM
    Pharmacotherapy; 2007 Aug; 27(8):1198-201. PubMed ID: 17655518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tigecycline resistance in Australian antibiotic-resistant Gram-negative bacteria.
    Iredell J; Thomas L; Power D; Mendes E
    J Antimicrob Chemother; 2007 Apr; 59(4):816-8. PubMed ID: 17353224
    [No Abstract]   [Full Text] [Related]  

  • 9. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.
    Garau J
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():198-202. PubMed ID: 18154548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidrug-resistant Gram-negative bacilli causing urinary tract infections: clinical considerations.
    Cunha BA
    J Chemother; 2011 Jun; 23(3):171-4. PubMed ID: 21742588
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic options for Acinetobacter baumannii infections.
    Vila J; Pachón J
    Expert Opin Pharmacother; 2008 Mar; 9(4):587-99. PubMed ID: 18312160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of tigecycline in the control of a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit.
    Jamal W; Salama M; Dehrab N; Al Hashem G; Shahin M; Rotimi VO
    J Hosp Infect; 2009 Jul; 72(3):234-42. PubMed ID: 19493588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii.
    Schafer JJ; Goff DA; Stevenson KB; Mangino JE
    Pharmacotherapy; 2007 Jul; 27(7):980-7. PubMed ID: 17594203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective.
    Curcio D
    J Clin Microbiol; 2008 May; 46(5):1892-3. PubMed ID: 18460636
    [No Abstract]   [Full Text] [Related]  

  • 15. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens.
    Poulakou G; Kontopidou FV; Paramythiotou E; Kompoti M; Katsiari M; Mainas E; Nicolaou C; Yphantis D; Antoniadou A; Trikka-Graphakos E; Roussou Z; Clouva P; Maguina N; Kanellakopoulou K; Armaganidis A; Giamarellou H
    J Infect; 2009 Apr; 58(4):273-84. PubMed ID: 19344841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of multiresistant Acinetobacter baumannii infections.
    Pachón J; Vila J
    Curr Opin Investig Drugs; 2009 Feb; 10(2):150-6. PubMed ID: 19197792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints.
    Ambrose PG; Meagher AK; Passarell JA; Van Wart SA; Cirincione BB; Rubino CM; Korth-Bradley JM; Babinchak T; Ellis-Grosse E
    Diagn Microbiol Infect Dis; 2009 Jan; 63(1):38-42. PubMed ID: 19073300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebral spinal fluid penetration of tigecycline in a patient with Acinetobacter baumannii cerebritis.
    Ray L; Levasseur K; Nicolau DP; Scheetz MH
    Ann Pharmacother; 2010 Mar; 44(3):582-6. PubMed ID: 20179255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favourable outcome in the treatment of carbapenem-resistant Enterobacteriaceae urinary tract infection with high-dose tigecycline.
    Brust K; Evans A; Plemmons R
    J Antimicrob Chemother; 2014 Oct; 69(10):2875-6. PubMed ID: 24879666
    [No Abstract]   [Full Text] [Related]  

  • 20. Tigecycline pharmacokinetic/pharmacodynamic update.
    MacGowan AP
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i11-6. PubMed ID: 18684702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.